RxDoctor Payments Data

Peggy Scharberg Chaffin, APRN

Primary Care · Missoula, MTNPI 1174234769

Payments from drug & device makers

What this record shows

Livanova USA, Inc. accounts for 83.2% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $2,200 and has fallen 84.4% since, to $342 in 2025. Among primary care clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,326in general payments, 2019–2025

Across 44 payments — averaging $98.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$4K
  • AbbVie$182
  • Catalyst Pharmaceuticals, Inc.$175
  • Pfizer$94
  • Neurelis, Inc.$43
  • Baxter Healthcare$42
  • plus $190 from 7 others

What the payments were for

  • Travel & lodging$2,56259%
  • Food & beverage$1,76541%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,326 in reported general payments places this provider in the 90th percentile of 20 primary care providers in Montana.

See all primary care providers in Montana

Medicare billing

Part B allowed, 2024
$37,932
Medicare patients
97
Services billed
269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyclarysOmaveloxolone14$448,232
Lacosamide82$14,322
Levetiracetam91$3,254
Primidone135$2,167
Zonisamide38$1,726
Lamotrigine80$1,533
Galantamine Hbr15$1,409
Carbamazepine ErCarbamazepine13$1,230
Entacapone16$1,099
Divalproex Sodium26$848
AmantadineAmantadine Hcl11$675
Oxcarbazepine21$651
Donepezil Hcl85$510
Carbidopa-Levodopa ErCarbidopa/Levodopa14$385
Gabapentin40$347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenSkyclarys$20$448,23214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 primary care providers in Montana.

Other primary care in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →